122 related articles for article (PubMed ID: 2837873)
1. Correlation of activity of chlorpromazine and respective hydroxy, dimethoxy and sulphoxide analogues on dopamine, muscarinic, histamine and calmodulin sites of action.
Palmer GC; Blosser JC; McCreedy SA; Barrantes MA; Manian AA
Xenobiotica; 1988 Mar; 18(3):277-89. PubMed ID: 2837873
[TBL] [Abstract][Full Text] [Related]
2. Comparison of inhibitory actions of chlorpromazine or its 7,8-dihydroxy and 7,8-dioxo-didesmethyl analogs on DA-sensitive adenylate cyclase and calmodulin activation of phosphodiesterase in rat striatum.
Palmer GC; Pajer KA; Manian AA
Arch Int Pharmacodyn Ther; 1985 Feb; 273(2):202-11. PubMed ID: 2988471
[TBL] [Abstract][Full Text] [Related]
3. Di- and trihydroxy analogs of chlorpromazine influence the central activity of adenylate cyclase and cyclic AMP phosphodiesterase.
Palmer GC; Legendre JL; Manian AA
Arch Int Pharmacodyn Ther; 1980 Sep; 247(1):59-70. PubMed ID: 6255882
[TBL] [Abstract][Full Text] [Related]
4. Histamine-, norepinephrine-, and dopamine-sensitive central adenylate cyclases: effects of chlorpromazine derivatives and butaclamol.
Palmer GC; Wagner HR; Palmer SJ; Manian AA
Arch Int Pharmacodyn Ther; 1978 Jun; 233(2):314-25. PubMed ID: 687395
[TBL] [Abstract][Full Text] [Related]
5. M-1 and M-2 muscarinic receptor-mediated inhibition of dopamine-sensitive adenylate cyclase in rat neostriatum: a permissive role for D-2 dopamine receptors.
Schoffelmeer AN; Hogenboom F; Mulder AH
J Pharmacol Exp Ther; 1988 May; 245(2):658-63. PubMed ID: 2452877
[TBL] [Abstract][Full Text] [Related]
6. Differential inhibition of calmodulin-sensitive phosphodiesterase and Ca++-adenosine triphosphatase by chlorpromazine-linked calmodulin.
Prozialeck WC; Wallace TL; Weiss B
J Pharmacol Exp Ther; 1987 Oct; 243(1):171-9. PubMed ID: 2822896
[TBL] [Abstract][Full Text] [Related]
7. Benzo [b]-promazines, chlorpromazine free radical and analino-N, N-dimethylpropylamine analogs influence rat striatal DA-adenylate cyclase and calmodulin-phosphodiesterase.
Sweatt JD; Palmer GC; Palmer SJ; Jackson TG; Manian AA
Arch Int Pharmacodyn Ther; 1982 Jun; 257(2):188-99. PubMed ID: 6287952
[TBL] [Abstract][Full Text] [Related]
8. Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum.
Onali P; Olianas MC; Gessa GL
Mol Pharmacol; 1985 Aug; 28(2):138-45. PubMed ID: 2410769
[TBL] [Abstract][Full Text] [Related]
9. Role of calmodulin-dependent phosphorylation in chronic sulpiride-induced striatal dopamine receptor supersensitivity.
Lau YS; Runice C; Dowd F
J Pharmacol Exp Ther; 1984 Apr; 229(1):32-7. PubMed ID: 6323689
[TBL] [Abstract][Full Text] [Related]
10. Differential inhibition of calcium-dependent and calmodulin-dependent enzymes by drug-calmodulin adducts.
Zhang SP; Prozialeck WC; Weiss B
Mol Pharmacol; 1990 Nov; 38(5):698-704. PubMed ID: 2146488
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of presynaptic muscarinic receptors regulating neurotransmitter release in the rat brain.
Raiteri M; Leardi R; Marchi M
J Pharmacol Exp Ther; 1984 Jan; 228(1):209-14. PubMed ID: 6141277
[TBL] [Abstract][Full Text] [Related]
12. Dopamine, acting through D-2 receptors, inhibits rat striatal adenylate cyclase by a GTP-dependent process.
Cooper DM; Bier-Laning CM; Halford MK; Ahlijanian MK; Zahniser NR
Mol Pharmacol; 1986 Feb; 29(2):113-9. PubMed ID: 3005824
[TBL] [Abstract][Full Text] [Related]
13. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
Rugsley TA; Davis MD; Akunne HC; Cooke LW; Whetzel SZ; MacKenzie RG; Shih YH; van Leeuwen DH; DeMattos SB; Georgic LM
J Pharmacol Exp Ther; 1995 Aug; 274(2):898-911. PubMed ID: 7636753
[TBL] [Abstract][Full Text] [Related]
14. Calmodulin antagonistic action of new 1,5-benzothiazepines derived from diltiazem.
Suzuki T; Ohashi M; Takaiti O; Harigaya S
Arzneimittelforschung; 1994 Jan; 44(1):3-6. PubMed ID: 8135875
[TBL] [Abstract][Full Text] [Related]
15. N-oxides of phenothiazine antipsychotics: effects on in vivo and in vitro estimates of dopaminergic function.
Lewis MH; Widerlöv E; Knight DL; Kilts CD; Mailman RB
J Pharmacol Exp Ther; 1983 Jun; 225(3):539-45. PubMed ID: 6134814
[TBL] [Abstract][Full Text] [Related]
16. On the involvement of multiple muscarinic receptor subtypes in the activation of phosphoinositide metabolism in rat cerebral cortex.
Forray C; el-Fakahany EE
Mol Pharmacol; 1990 Jun; 37(6):893-902. PubMed ID: 2163015
[TBL] [Abstract][Full Text] [Related]
17. Dissociation between muscarinic receptor-mediated inhibition of adenylate cyclase and autoreceptor inhibition of [3H] acetylcholine release in rat hippocampus.
Vickroy TW; Cadman ED
J Pharmacol Exp Ther; 1989 Dec; 251(3):1039-44. PubMed ID: 2557410
[TBL] [Abstract][Full Text] [Related]
18. Comparative antidopaminergic properties of thioridazine, mesoridazine and sulforidazine on the corpus striatum.
Niedzwiecki DM; Cubeddu LX; Mailman RB
J Pharmacol Exp Ther; 1989 Jul; 250(1):117-25. PubMed ID: 2746491
[TBL] [Abstract][Full Text] [Related]
19. Muscarinic stimulation of adenylate cyclase activity of rat olfactory bulb. II. Characterization of the antagonist sensitivity and comparison with muscarinic inhibitions of the enzyme in striatum and heart.
Olianas MC; Onali P
J Pharmacol Exp Ther; 1991 Nov; 259(2):680-6. PubMed ID: 1658307
[TBL] [Abstract][Full Text] [Related]
20. Muscarinic cholinergic receptors of two cell lines that regulate cyclic AMP metabolism by different molecular mechanisms.
Evans T; Smith MM; Tanner LI; Harden TK
Mol Pharmacol; 1984 Nov; 26(3):395-404. PubMed ID: 6092892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
